These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32738410)

  • 1. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Mani RS; Ciniero G; Tuszynski JA; Weinfeld M; West FG
    Eur J Med Chem; 2020 Oct; 204():112658. PubMed ID: 32738410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
    Elmenoufy AH; Gentile F; Jay D; Karimi-Busheri F; Yang X; Soueidan OM; Weilbeer C; Mani RS; Barakat KH; Tuszynski JA; Weinfeld M; West FG
    J Med Chem; 2019 Sep; 62(17):7684-7696. PubMed ID: 31369707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
    Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
    Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
    Gentile F; Barakat KH; Tuszynski JA
    Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.
    Chapman TM; Gillen KJ; Wallace C; Lee MT; Bakrania P; Khurana P; Coombs PJ; Stennett L; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4097-103. PubMed ID: 26318993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.
    Jordheim LP; Barakat KH; Heinrich-Balard L; Matera EL; Cros-Perrial E; Bouledrak K; El Sabeh R; Perez-Pineiro R; Wishart DS; Cohen R; Tuszynski J; Dumontet C
    Mol Pharmacol; 2013 Jul; 84(1):12-24. PubMed ID: 23580445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM; Melton DW
    Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
    Ciniero G; Elmenoufy AH; Gentile F; Weinfeld M; Deriu MA; West FG; Tuszynski JA; Dumontet C; Cros-Perrial E; Jordheim LP
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):259-267. PubMed ID: 33399940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domain mapping of the DNA binding, endonuclease, and ERCC1 binding properties of the human DNA repair protein XPF.
    McCutchen-Maloney SL; Giannecchini CA; Hwang MH; Thelen MP
    Biochemistry; 1999 Jul; 38(29):9417-25. PubMed ID: 10413517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCAF7 is required for maintaining the cellular levels of ERCC1-XPF and nucleotide excision repair.
    Kawara H; Akahori R; Wakasugi M; Sancar A; Matsunaga T
    Biochem Biophys Res Commun; 2019 Oct; 519(1):204-210. PubMed ID: 31493872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.
    Tsodikov OV; Enzlin JH; Schärer OD; Ellenberger T
    Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11236-41. PubMed ID: 16076955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Hydroxyimides and hydroxypyrimidinones as inhibitors of the DNA repair complex ERCC1-XPF.
    Chapman TM; Wallace C; Gillen KJ; Bakrania P; Khurana P; Coombs PJ; Fox S; Bureau EA; Brownlees J; Melton DW; Saxty B
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4104-8. PubMed ID: 26321360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
    DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
    Kirschner K; Melton DW
    Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells.
    Niedernhofer LJ; Essers J; Weeda G; Beverloo B; de Wit J; Muijtjens M; Odijk H; Hoeijmakers JH; Kanaar R
    EMBO J; 2001 Nov; 20(22):6540-9. PubMed ID: 11707424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.